Effect of an Ayurvedic Intervention (Ayush-64) as a Stand-Alone Treatment in Mild to Moderate COVID-19: An Exploratory Prospective Single-Arm Clinical Trial

An Ayurvedic polyherbal formulation (Ayush-64) was repurposed for use in mild to moderate COVID-19 cases based on the supportive evidence obtained from a pilot study on its effect on Influenza like illness (ILI) and molecular docking study which revealed that several compounds isolated from Ayush-64 demonstrated antiviral activity. The study aims at evaluating the effect of an Ayurvedic intervention (Ayush-64) in mild to moderate COVID-19 patients. A prospective single arm, pilot study in mild to moderate COVID-19 patients.  The study was conducted at Chaudhary Brahm Prakash Ayurved Charak Sansthan (CBPACS), New Delhi, India. A total of 37 COVID-19 participants confirmed through RT-PCR were included in the study. The proportion of participants with negative SARS-CoV-2 on nasal or throat swab in a 2-day consecutive real-time RT-PCR test was evaluated as the secondary outcome. In the study, 86.1% of participants demonstrated clinical recovery with 14 days of use of Ayush-64 as stand-alone treatment without any other conventional medicines, out of which 75% clinically recovered within 8 days. Further, 69.4% of participants turned negative by the 15th day, out of which 50% became COVID-19 negative on the 8th day. No AE/ ADR was observed during the study. Ayush-64 may significantly facilitate clinical improvement in terms of duration for clinical recovery and attaining negative conversion in mild to moderate COVID-19 cases.